IMM Stock Overview A late-stage biotechnology company, engages in developing novel LAG-3 related immunotherapies for cancer and autoimmune diseases in Australia. More details
Rewards Risk Analysis See All Risk Checks Capture your thoughts, links and company narrative
Immutep Limited Competitors Price History & Performance
Summary of share price highs, lows and changes for Immutep Historical stock prices Current Share Price AU$0.37 52 Week High AU$0.48 52 Week Low AU$0.23 Beta 1.93 1 Month Change 13.85% 3 Month Change 14.73% 1 Year Change 6.47% 3 Year Change -26.73% 5 Year Change 39.62% Change since IPO 2.78%
Recent News & Updates
Less than half of directors are independent Dec 24
Immutep Announces Initial Safety Data from First-in-Human Phase I Trial Evaluating IMP761 Dec 18
Immutep Limited and Monash University Announce First Publication Detailing How Human LAG-3 Binds to MHC Class II Dec 16
Immutep Limited Reports Promising New Data in Head and Neck Cancer At ESMO Immuno-Oncology 2024 Dec 12
Immutep Limited Announces Initiation of TACTI-004 Phase III Trial in First Line Non-Small Cell Lung Cancer Dec 10
Immutep Limited, Annual General Meeting, Nov 22, 2024 Oct 10 See more updates
Less than half of directors are independent Dec 24
Immutep Announces Initial Safety Data from First-in-Human Phase I Trial Evaluating IMP761 Dec 18
Immutep Limited and Monash University Announce First Publication Detailing How Human LAG-3 Binds to MHC Class II Dec 16
Immutep Limited Reports Promising New Data in Head and Neck Cancer At ESMO Immuno-Oncology 2024 Dec 12
Immutep Limited Announces Initiation of TACTI-004 Phase III Trial in First Line Non-Small Cell Lung Cancer Dec 10
Immutep Limited, Annual General Meeting, Nov 22, 2024 Oct 10
Immutep Limited Announces Resignation of Anne Anderson as Independent Non-Executive Director Oct 04
Immutep Completes Patient Enrolment in Randomised Phase II of AIPAC-003 Trial in Metastatic Breast Cancer Oct 03
Immutep Limited Announces New Data from Eftisarc-Neo Phase II Evaluating Novel Triple Combination Including Immutep's Efti in Soft Tissue Sarcoma Sep 19
Immutep Limited Announces Positive Efficacy and Safety Results from the TACTI-003 Phase IIb Trial Evaluating Eftilagimod Alpha Sep 16
Full year 2024 earnings released: AU$0.036 loss per share (vs AU$0.045 loss in FY 2023) Aug 30
No longer forecast to breakeven Aug 30
Immutep Limited Announces Late-Breaking Abstract in Head & Neck Cancer Selected for Oral Presentation at ESMO Congress Aug 21
Immutep Announces First Participant Dosed in Phase I Study of Imp761, A First in Class Agonist Lag-3 Antibody Aug 14
Immutep Announces Successful Meeting with FDA on Phase III Design in Non-Small Cell Lung Cancer Jul 23
Immutep Limited Receives Regulatory Clearance for Phase I Study of First-In-Class Lag-3 Agonist Antibody Designed to Treat Autoimmune Diseases Jul 17
Immutep Reports Positive Results in First Line Head and Neck Squamous Cell Carcinoma Patients with Negative Pd-L1 Expression Jul 12
New minor risk - Shareholder dilution Jun 13
No longer forecast to breakeven Jun 05
Immutep Limited Announces Clinical Collaboration with Msd to Evaluate Efti in Combination with Keytruda®? (Pembrolizumab) in Pivotal Phase Iii Trial Jun 05
Immutep Limited Presents Data from Safety Lead-In Phase of AIPAC-003 at ESMO Breast 2024 May 16
Immutep Limited Reports Positive Initial Clinical Data Reported from Efti Combined with Radiotherapy and Checkpoint Inhibitor from Phase II Trial in Soft Tissue Sarcoma May 03
Immutep Limited Announces Positive Preliminary Topline Results from TACTI-003 Cohort B Apr 27
New minor risk - Profitability Apr 25
Immutep Limited Appoints Leading Research Institute to Conduct First-In-Human Phase I Study of IMP761 Apr 20
Immutep Limited Receives Positive Feedback from the Spanish Medicines Agency for Upcoming Tacti-004 Registrational Trial in Metastatic Non-Small Cell Lung Cancer Apr 17
Immutep Limited Announces First Clinical Data from 90Mg Dosing of Efti Mar 05
Immutep Limited Announces First Patient Dosed in Trial Evaluating Efti and the Anti-PD-L1 Therapy BAVENCIO in Metastatic Urothelial Cancer Jan 05
Immutep Limited Receives Constructive Regulatory Feedback on TACTI-004 Registrational Trial in Metastatic Non-Small Cell Lung Cancer Dec 21
Immutep Limited Completes Enrollment in TACTI-003 Phase IIb Trial of Efti and KEYTRUDA(R) in First Line Metastatic or Recurrent Head and Neck Squamous Cell Carcinoma Nov 10
Immutep Announces New Biomarker Data from Tacti-002 Phase II in First Line Non-Small Cell Lung Cancer Nov 04
Immutep Limited Reports Promising Clinical Data from Insight-003 Trial at ESMO Congress 2023 Oct 25
Immutep Limited Announces Excellent New Clinical Data from the TACTI-002 / KEYNOTE-798 Phase II Trial Evaluating Eftilagimod Alpha Oct 23
Immutep Limited Announces Commercial Manufacturing of Eftilagimod Alpha at 2000L Scale Granted Authorization for Clinical Trial Use Sep 22
Immutep Limited, Annual General Meeting, Oct 24, 2023 Sep 08
Full year 2023 earnings released: AU$0.045 loss per share (vs AU$0.038 loss in FY 2022) Aug 31 Immutep Limited Receives Positive Scientific Advice from Committee for Medicinal Products for Human Use of European Medicines Agency for Continued Development of Eftilagimod Alpha Aug 03
Immutep Limited Announces First Patient Dosed in Chemotherapy-Free Triple Combination Phase II Trial Targeting Soft Tissue Sarcoma Jul 29
Forecast to breakeven in 2026 Jun 30 Immutep Limited Doses First Patient in AIPAC-003 Phase II/III Trial for Metastatic Breast Cancer
Immutep Limited Announces Efti in Combination with Pembrolizumab Achieves Excellent Initial Overall Survival Benefit in 1st Line Non-Small Cell Lung Cancer May 18 Immutep Limited Receives Positive Feedback from FDA on Late-Stage Clinical Development of Eftilagimod Alpha in Non-Small Cell Lung Cancer May 17
No longer forecast to breakeven Mar 14
First half 2023 earnings released: AU$0.024 loss per share (vs AU$0.019 loss in 1H 2022) Feb 25
Immutep Reaches Enrolment Target for INSIGHT-003 Trial in 1st Line NSCLC Feb 07
Immutep Limited Announces Update on INSIGHT-003 Trial in NSCLC Feb 06
Immutep Limited Enrolls and Randomised over 50% of the Planned 154 Patients in the Tacti-003 Phase IIB Trial Jan 04 Immutep Limited Announces the Results of Positive Follow-Up Type C Meeting with the US Food and Drug Administration Dec 24
Immutep Limited Announces the Successful Scale-Up of the Manufacturing of its Lead Product Candidate Eftilagimod Alpha Dec 10
Immutep Limited Announces GMP Manufacturing Process Developed for IMP761, a First-in-Class LAG-3 Agonist for Autoimmune Disease Dec 06
Less than half of directors are independent Nov 17 Immutep Limited Announces Compelling Clinical Results from Phase II Trial Utilizing its First-in-Class Soluble LAG-3 Protein, Eftilagimod Alpha, in 1st Line NSCLC at SITC 2022 Annual Meeting
Immutep Limited Announces Independent Data Monitoring Committee Positive Recommendation to Continue TACTI-003 Trial as Planned Oct 27
Immutep Limited Announces the United States Food and Drug Administration (Fda) Has Granted Fast Track Designation to Eftilagimod Alpha Oct 06
Immutep Limited, Annual General Meeting, Nov 23, 2022 Sep 21 Immutep Clinical Development Update for its LAG-3 Antigen Presenting Cell Activator Candidate Eftilagimod Alpha Sep 15
Immutep Clinical Development Update for its LAG-3 Antigen Presenting Cell Activator Candidate Eftilagimod Alpha Sep 14
Immutep Appoints Frederic Triebel as Executive Director Sep 13
Immutep Limited Announces Investigator-Initiated Phase Ii Trial Evaluating LAG-3 Candidate Eftilagimod Alpha (Efti) in Soft Tissue Sarcoma Sep 07
Immutep Limited Announces Investigator-Initiated Phase Ii Trial Evaluating LAG-3 Candidate Eftilagimod Alpha (Efti) in Soft Tissue Sarcoma Sep 06
No longer forecast to breakeven Sep 02
Immutep Limited Grants Japanese Patent for Eftilagimod Alpha, a Soluble Lag-3 Protein, in Combination with a PD-1 Pathway Inhibitor Aug 31
Immutep Limited Reports New Positive Interim Data from its Phase II Study of LAG-3 Candidate, Eftilagimod Alpha, in 2nd Line PD-X Refractory NSCLC Aug 02
Immutep Limited Provides an Update on the Ongoing Development of Its Product Candidates, eftilagimod alpha and IMP76 for the Quarter Ended 30 June 2022 Jul 29
Forecast to breakeven in 2025 Jul 01
Immutep Limited Reports Positive Overall Response Rate in Its Phase II Clinical Trial in 1st line NSCLC for PD-L1 All-Comers Jun 04
High number of new and inexperienced directors Jun 03
Immutep Limited Announces Executive Changes May 18
Immutep Limited Presents New and Significant Data from the AIPAC Study May 05
Immutep Limited Provides Update on the Ongoing Development of Its Product Candidates, Eftilagimod Alpha and IMP761 for the Quarter Ended 31 March 2022 May 02
Immutep’S Efti in Combination with Msd’S Pembrolizumab Shows Encouraging Antitumor Activity in Difficult to Treat 2Nd Line Metastatic Lung Cancer Patients Mar 31
Immutep Limited Announces New Interim Data in 2nd Line Metastatic NSCLC from Its Phase II TACTI-002 Trial Mar 30
High number of new directors Mar 29
First half 2022 earnings: EPS in line with expectations, revenues disappoint Mar 01
Immutep Limited Appoints Lucy Turnbull as Non-Executive Director Feb 25
Immutep Limited to Present New Data from the Phase II TACTI-002 Study of Efti at ESMO’s European Lung Cancer Congress 2022 Feb 19
Immutep Limited to Present New Data from the Phase II TACTI-002 Study of Efti At ESMO's European Lung Cancer Congress 2022 Feb 18
Immutep Limited Announces Demise of Grant Chamberlain, Non-Executive Director Feb 02
Immutep Limited Provides an Update on the Ongoing Development of Its Product Candidates, Eftilagimod Alpha Jan 26
No longer forecast to breakeven Jan 06
Immutep Limited Reports Good Safety from First Five Patients in the INSIGHT-003 study Dec 03
Immutep to Present Final Overall Survival Data from Phase IIb AIPAC as a Late Breaking Poster Presentation At SITC 2021 Sep 23
Forecast to breakeven in 2024 Sep 23
Full year 2021 earnings released: AU$0.05 loss per share (vs AU$0.034 loss in FY 2020) Sep 02
Immutep Limited Provides an Update on the Ongoing Development of Its Product Candidates Jul 15
Immutep Receives FDA and IRB Approval in the US for Phase IIb TACTI-003 Trial in HNSCC Jul 07
Forecast to breakeven in 2024 Jun 30 Immutep Limited Signs Agreement to Commence New Phase I Trial, Called Insight-003, to Evaluate the Combination of Lead Product Candidate Eftilagimod Alpha
Immutep Limited Reveals a New anti-LAG-3 Research Program Jun 08
Immutep Limited Reports Positive Data from Its Tacti-002 Phase Ii Study of Lag-3 Therapy, Efti, At Asco 2021 Jun 05
Immutep Limited Reports Positive Final Data from Insight-004 Trial Jun 04
Immutep Limited Announces Publication of TACTI-002 and INSIGHT-004 Abstracts for ASCO 2021 Annual Meeting May 21 Shareholder Returns IMM AU Biotechs AU Market 7D 8.8% 1.9% 0.5% 1Y 6.5% 3.9% 7.4%
See full shareholder returns
Return vs Market: IMM matched the Australian Market which returned 7.4% over the past year.
Price Volatility Is IMM's price volatile compared to industry and market? IMM volatility IMM Average Weekly Movement 7.2% Biotechs Industry Average Movement 10.0% Market Average Movement 8.0% 10% most volatile stocks in AU Market 16.9% 10% least volatile stocks in AU Market 3.0%
Stable Share Price: IMM has not had significant price volatility in the past 3 months compared to the Australian market.
Volatility Over Time: IMM's weekly volatility (7%) has been stable over the past year.
About the Company Immutep Limited, a late-stage biotechnology company, engages in developing novel LAG-3 related immunotherapies for cancer and autoimmune diseases in Australia. Its lead product candidate is the eftilagimod alpha (efti or IMP321), a soluble LAG-3lg fusion based, which is in clinical development for the treatment of different types of cancers. The company’s product pipeline also includes TACTI-004, which is in phase III clinical trial for the treatment of first line non-small cell lung cancer (1L NSCLC); TACTI-003, which is in phase IIb clinical trial to treat first line head and neck squamous cell carcinoma (HNSCC); TACTI-002, which in phase II trial for the treatment NSCLC and HNSCC; AIPAC-003, which is in phase II/III clinical trial to treat metatastic breast cancer; and EFTISARC-NEO, which is in phase II clinical trial for the treatment of soft tissue sarcoma.
Show more Immutep Limited Fundamentals Summary How do Immutep's earnings and revenue compare to its market cap? IMM fundamental statistics Market cap AU$530.92m Earnings (TTM ) -AU$42.72m Revenue (TTM ) AU$3.84m
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) IMM income statement (TTM ) Revenue AU$3.84m Cost of Revenue AU$41.55m Gross Profit -AU$37.70m Other Expenses AU$5.01m Earnings -AU$42.72m
Last Reported Earnings
Jun 30, 2024
Earnings per share (EPS) -0.029 Gross Margin -981.42% Net Profit Margin -1,111.87% Debt/Equity Ratio 0.5%
How did IMM perform over the long term?
See historical performance and comparison
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2024/12/31 08:26 End of Day Share Price 2024/12/31 00:00 Earnings 2024/06/30 Annual Earnings 2024/06/30
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources Immutep Limited is covered by 17 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution Joel Beatty Baird Thomas Wakim Bell Potter Tara Speranza Bell Potter
Show 14 more analysts 
